Contributor Disclosures for Amebiasis

Role Name Disclosure Details Author  Maria A Horga, MD, Assistant Professor, Department of Pediatric Infectious Diseases, Bristol-Myers Squibb Nothing to disclose Details Coauthor  Thomas R Naparst, MD, Clinical Instructor in Emergency Medicine, New York University School of Medicine; Consulting Staff, Department of Emergency Medicine, New York Downtown Hospital Nothing to disclose Details Coauthor  Vinod K Dhawan, MD, FACP, FRCP(C), Professor, Department of Clinical Medicine, University of California at Los Angeles; Professor of Medicine, Charles R Drew University of Medicine and Science; Chief, Division of Infectious Diseases, MLK-Harbor Hospital Pfizer Inc Details Medical Editor  Michael D Nissen, MBBS, BMedSc, FRACP, FRCPA, Associate Professor in Biomolecular, Biomedical Science & Health, Griffith University; Director of Infectious Diseases and Unit Head of Queensland Paediatric Infectious Laboratory, Sir Albert Sakzewski Viral Research Centre, Royal Children's Hospital Nothing to disclose Details Pharmacy Editor  Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc Avanir Pharma Details Managing Editor  Martin Weisse, MD, Program Director, Associate Professor, Department of Pediatrics, West Virginia University Nothing to disclose Details CME Editor  Robert W Tolan Jr, MD, Chief of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine GlaxoSmithKline MedImmune MedImmune Merck Novartis sanofi pasteur sanofi pasteur sanofi pasteur Tap Details Chief Editor  Russell W Steele, MD, Professor and Vice Chairman, Department of Pediatrics, Head, Division of Infectious Diseases, Louisiana State University Health Sciences Center None Details Contributor Disclosure Contributor: Contributor Disclosure: Maria A Horga, Author  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Thomas R Naparst, Coauthor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Vinod K Dhawan  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Pfizer Inc None None   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Michael D Nissen, Medical Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Mary L Windle  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Pfizer Inc Stock Investment from broker recommendation   Avanir Pharma Stock Investment from broker recommendation   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Martin Weisse, Managing Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Robert W Tolan, Jr  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** GlaxoSmithKline Honoraria Speaking and teaching   MedImmune Honoraria Consulting   MedImmune Honoraria Speaking and teaching   Merck Honoraria Speaking and teaching   Novartis Honoraria Speaking and teaching   sanofi pasteur Grant/research funds Unrestricted research grant   sanofi pasteur Honoraria Consulting   sanofi pasteur Honoraria Speaking and teaching   Tap Honoraria Speaking and teaching   Off label or investigational use of medication Several medications used in routine pediatric practice are used in an off-label fashion. We participate in a research studies of off-label uses of medications through the NIAID Antiviral Collaborative Study Group. CONTRIBUTOR DISCLOSURE FORM Contributor Name: Russell W Steele  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** None None None   Off label or investigational use of medication none